- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06053242
Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain (ADAPT)
February 5, 2024 updated by: Creative Medical Technology Holdings Inc
A Double-blinded, Randomized, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Effectiveness of CELZ-201-DDT Administered by Intramuscular Injection for the Treatment of Chronic Lower Back Pain in Patients With Degenerative Disc Disease
The brief purpose of this research study is to learn about the safety, tolerability, and efficacy of paraspinal intramuscular injection of CELZ-201-DDT in patients with chronic lower back pain.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
This study is a double-blinded, randomized, placebo-controlled, dose escalation Phase 1/2a study.
The objective is to determine the safety, tolerability, and efficacy of CELZ-201-DDT administered as an intramuscular injection for the treatment of lower back pain in patients with Degenerative Disc Disease.
Subjects who meet all criteria for inclusion will be enrolled and randomized into either low, medium or high dose of CELZ-201-DDT versus Placebo, with a total of 30 subjects enrolled.
Each dosing cohort will contain ten subjects (n=10), with eight subjects (n=8) receiving the investigational product and two subjects (n=2) randomized to receive placebo.
Each subject will receive six paraspinal intramuscular injections (three injections per side) of either CELZ-201-DDT or placebo into the lumbar musculature under direct ultrasound guidance.
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Creative Medical Technology
- Phone Number: (702) 588-1890
- Email: clinicaltrials@creativemedicaltechnology.com
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami
-
Contact:
- Creative Medical
- Phone Number: 702-588-1890
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Ability of participant to understand and the willingness to sign a written informed consent document.
- Between 18-80 years of age and may be of either gender or any race.
- Subjects must have failed at least two standard of care (SOC) therapies before being enrolled in the study: 1) exercise/physical therapy; 2) oral analgesic including nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; 3) skeletal muscle relaxants. Subjects must have tried each SOC therapy for at least 3 months before failure is determined.
- Patients must have failed the SOC therapies within 12 months of enrollment in the clinical trial.
- Proof for one of the following tests already performed in the clinical care of the patient for lower back pain: 1) MRI scan demonstrating at least one disc level with grade II or greater disc degeneration using the Pfirrmann grading system; 2) Oswestry Disability Index for Back Pain score of 21-80%; 3) Visual Analogue Scale for pain of >5 on a scale of 0-10.
- Female subjects must not be breast feeding and must have no intention to become pregnant during the study, and she is using contraceptive drugs or devices.
- Any male subject must agree to use contraceptives and not donate sperm during the study.
Exclusion Criteria:
- History of cancer in the last five years.
- Spinal infections and spinal tumors.
- Renal insufficiency requiring dialysis or an eGFR of less than 60 mL/min/1.73m2.
- ALT, AST greater than 2 times or Total Bilirubin 1.5 times the upper limit of the normal range.
- Positive pregnancy test.
- History of blood cell diseases.
- Uncontrolled diabetes mellitus - HgA1c >8%.
- Uncontrolled hypertension defined as a systolic blood pressure of >140 mmHg or diastolic blood pressure of >90 mmHg at the time of screening. If subjects have their hypertension appropriately treated, then they would be eligible to enroll.
- Patients known to have any active infection, including infection of the injection site(s), and/or any active systemic or local infection.
- Patients on chronic immunosuppressive transplant therapy. Patients receiving <5 mg of Prednisone daily may be included.
- Subjects having a concomitant life-threatening disease in which their life expectancy is estimated to be less than 2 years.
- Recent smoking history or substance abuse (within six weeks).
- Heavy alcohol use (greater than 14 drinks per week for men or 7 drinks per week for women per NIAAA)
- Use of an investigational drug, device or product, or participation in a drug research study within a period of 30 days prior to receiving study treatment.
- Any patient who has received gene therapy in the past.
- Subjects who are currently on opioid medication(s).
- Body Mass Index (BMI) > 40 kg/m2.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low Dose
Subjects in the low dose arm will receive a single administration of either 6x10^6 cells (n=8) or a placebo injection (n=2).
Each subject will receive six paraspinal intramuscular injections (three injections per side) of either CELZ-201-DDT or placebo into the lumbar musculature under direct ultrasound guidance.
|
Subjects enrolled in the trial will receive CELZ-201-DDT at the specified dose into the lumbar paraspinal musculature.
Each subject will receive a total of six injections, three injections on each side, under direct ultrasound guidance.
Subjects will receive a placbeo injection into the lumbar paraspinal musculature.
Each subject will receive a total of six injections, three injections on each side, under direct ultrasound guidance.
|
Experimental: Medium Dose
Subjects in the medium dose arm will receive a single administration of either 12x10^6 cells (n=8) or a placebo injection (n=2).
Each subject will receive six paraspinal intramuscular injections (three injections per side) of either CELZ-201-DDT or placebo into the lumbar musculature under direct ultrasound guidance.
|
Subjects enrolled in the trial will receive CELZ-201-DDT at the specified dose into the lumbar paraspinal musculature.
Each subject will receive a total of six injections, three injections on each side, under direct ultrasound guidance.
Subjects will receive a placbeo injection into the lumbar paraspinal musculature.
Each subject will receive a total of six injections, three injections on each side, under direct ultrasound guidance.
|
Experimental: High Dose
Subjects in the high dose arm will receive a single administration of either 24x10^6 cells (n=8) or a placebo injection (n=2).
Each subject will receive six paraspinal intramuscular injections (three injections per side) of either CELZ-201-DDT or placebo into the lumbar musculature under direct ultrasound guidance.
|
Subjects enrolled in the trial will receive CELZ-201-DDT at the specified dose into the lumbar paraspinal musculature.
Each subject will receive a total of six injections, three injections on each side, under direct ultrasound guidance.
Subjects will receive a placbeo injection into the lumbar paraspinal musculature.
Each subject will receive a total of six injections, three injections on each side, under direct ultrasound guidance.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate safety of CELZ-201-DDT administered as intramuscular injections in subjects experiencing chronic lower back pain at a low, medium, or high dose.
Time Frame: 6 months
|
The primary outcome will be evaluated by the incidence of grade 3 or 4 or serious adverse events in all dosing cohorts at 6 months.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the potential efficacy of CELZ-201-DDT therapy in terms of pain alleviation and improved mobility in subjects experiencing chronic low back pain.
Time Frame: 12 months
|
The secondary outcome will be evaluated by change in pain as judged by the Visual Analogue Score (VAS), using a score of 0-10.
|
12 months
|
Evaluate the potential efficacy of CELZ-201-DDT therapy in terms of pain alleviation and improved mobility in subjects experiencing chronic low back pain.
Time Frame: 12 months
|
The secondary outcome will be evaluated by change in disability as judged by the Oswestry Disability Index (ODI) for back pain.
|
12 months
|
Evaluate the potential efficacy of CELZ-201-DDT therapy in terms of pain alleviation and improved mobility in subjects experiencing chronic low back pain.
Time Frame: 12 months
|
The secondary outcome will be evaluated by change in requirements for pain medications to manage back pain.
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
April 1, 2024
Primary Completion (Estimated)
April 1, 2025
Study Completion (Estimated)
April 1, 2026
Study Registration Dates
First Submitted
September 17, 2023
First Submitted That Met QC Criteria
September 21, 2023
First Posted (Actual)
September 25, 2023
Study Record Updates
Last Update Posted (Estimated)
February 7, 2024
Last Update Submitted That Met QC Criteria
February 5, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CELZ-201-ADAPT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Low-back Pain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Iran University of Medical SciencesNot yet recruitingLow Back Pain | Chronic Low-back Pain | Chronic Non-specific Low Back Pain | Cupping Therapy
-
Federal University of Minas GeraisRecruitingBack Pain | Low Back Pain | Chronic Low-back Pain | Back Pain Lower Back ChronicBrazil
-
University of Colorado, BoulderNational Institutes of Health (NIH); Radiological Society of North America; Psychophysiologic... and other collaboratorsCompletedChronic Pain | Back Pain Lower Back Chronic | Back Pain, LowUnited States
-
Federal University of ParaíbaCompletedChronic Low Back Pain | Nonspecific Chronic Low Back Pain
-
Faculdade de Ciências Médicas da Santa Casa de...CompletedLow Back Pain, Mechanical | Low Back Pain, Postural | Lower Back Pain Chronic | Low Back Pain, Posterior CompartmentBrazil
-
Presidio Medical, IncRecruitingChronic Pain | Chronic Low-back PainAustralia
-
Spaulding Rehabilitation HospitalHighland Instruments, Inc.Active, not recruitingChronic Pain | Chronic Low Back PainUnited States
-
University of WashingtonNational Center for Complementary and Integrative Health (NCCIH)Active, not recruiting
-
Dan RhonNational Center for Complementary and Integrative Health (NCCIH); 59th Medical... and other collaboratorsRecruitingLow Back Pain | Chronic Pain | Surgery | Back Pain Lower Back Chronic | Back Pain, LowUnited States
Clinical Trials on CELZ-201-DDT
-
Creative Medical Technology Holdings IncRecruitingDiabetes Mellitus, Type 1 | Type 1 DiabetesUnited States
-
TWi Biotechnology, Inc.CompletedType 2 Diabetes MellitusUnited States, Taiwan
-
Modulation Therapeutics, Inc.H. Lee Moffitt Cancer Center and Research InstituteRecruitingUveal Melanoma | MetastaticUnited States
-
Royal Prince Alfred Hospital, Sydney, AustraliaCompleted
-
Suzhou Connect Biopharmaceuticals, Ltd.Active, not recruiting
-
Peking UniversityCSPC Ouyi Pharmaceutical Co., Ltd.Recruiting
-
Orion Corporation, Orion PharmaEndo PharmaceuticalsCompleted
-
QurAlis CorporationRecruitingAmyotrophic Lateral SclerosisCanada, Germany, Netherlands, Ireland, United Kingdom, Belgium
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsCompletedPsoriasisGermany, Israel, Poland, Spain
-
PegBio Co., Ltd.CompletedType2 Diabetes MellitusChina